-- Founders Metals (FDR.V) 周四公布了其位于苏里南的 Antino 金矿项目 Lower Antino 靶区高品位金矿勘探结果。 该公司表示，此次勘探结果包括一段 6.0 米、金品位为 12.95 克/吨的矿段，是 Lower Antino 靶区“重要的高品位”矿段。该公司补充说，持续的系统性钻探将沿走向扩大矿化系统。 “虽然该系统一直以来都存在范围较广、品位较低的矿化，但此次发现表明存在高品位矿化成分——这正是我们一直在积极探索的特征，”首席执行官 Colin Padget 表示。“本次公布的钻探结果将继续扩大 Lower Antino 靶区的矿化范围，我们将把这些结果纳入我们的地质模型，以便在项目推进过程中更好地确定矿化的几何形态和连续性。” 该公司股票在多伦多证券交易所创业板 (TSX Venture Exchange) 的最新交易价格下跌 0.09 美元，至 4.81 美元。
Price: $4.81, Change: $-0.09, Percent Change: -1.84%
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%